References Library
A complete bibliography of peer-reviewed publications, clinical trial registrations, and regulatory documents cited throughout this knowledge base. All references follow academic citation standards.
23 references indexed
2025
-
Jastreboff AM, le Roux CW, Engberg S, et al.
Retatrutide Phase 3 Trial in Obesity with Knee Osteoarthritis (TRIUMPH-4)
New England Journal of Medicine (2025)
phase-3 triumph-4 obesity osteoarthritis weight-loss -
Eli Lilly and Company
Lilly's retatrutide (LY3437943) showed statistically significant and clinically meaningful results in TRIUMPH-4 Phase 3 trial
Eli Lilly Press Release (2025)
phase-3 triumph-4 press-release obesity osteoarthritis
2024
-
Aronne LJ, Sattar N, Horn DB, et al.
Continued weight loss and cardiometabolic improvements with retatrutide: extended analysis of the phase 2 obesity trial
Obesity . 32 : 536-546 (2024)
phase-2 obesity weight-loss cardiometabolic -
Aronne LJ, Sattar N, Horn DB, et al.
Retatrutide Phase 2 body composition substudy results
Obesity . 32 : 1425-1438 (2024)
phase-2 body-composition lean-mass fat-mass -
Coskun T, Roell WC, Urva S, et al.
Pharmacological profile and mechanisms of the triple GIP/GLP-1/glucagon receptor agonist retatrutide
Diabetes, Obesity and Metabolism . 26 : 816-828 (2024)
pharmacology mechanism receptor-binding -
Eli Lilly and Company
Lilly provides update on retatrutide phase 3 clinical development program for obesity and type 2 diabetes
Eli Lilly Press Release (2024)
regulatory phase-3 development press-release -
Frias JP, Jastreboff AM, le Roux CW, et al.
Metabolic outcomes with retatrutide in adults with type 2 diabetes and obesity: comprehensive analysis from the phase 2 program
Diabetes Care . 47 : 1084-1093 (2024)
metabolic type-2-diabetes liver-fat lipids -
Frias JP, Hsia S, Engberg S, et al.
Retatrutide cardiovascular safety and metabolic parameters in the Phase 2 obesity trial
Diabetes, Obesity and Metabolism (2024)
cardiovascular safety phase-2 metabolic -
Garvey WT, Frias JP, Jastreboff AM, et al.
Body composition changes with retatrutide in the phase 2 obesity trial: a dual-energy x-ray absorptiometry substudy
Nature Medicine . 30 : 1382-1391 (2024)
body-composition obesity fat-mass lean-mass -
Hartman ML, Shanahan WR, Engberg S, et al.
TRIUMPH Program Phase 3 design for retatrutide in obesity and type 2 diabetes
Diabetes . 73 (2024)
phase-3 triumph study-design -
le Roux CW, Hankosky ER, Wang H, et al.
Retatrutide in chronic kidney disease: design of a phase 2 trial
Kidney International Reports (2024)
phase-2 ckd chronic-kidney-disease renal -
le Roux CW, Steen O, Lucas KJ, et al.
Retatrutide effects on kidney parameters in participants with overweight or obesity: A Phase 2 substudy
The Lancet Diabetes & Endocrinology (2024)
phase-2 kidney renal albuminuria egfr -
Ryan DH, Yockey SR, Garvey WT
GLP-1 receptor agonists and obstructive sleep apnea
Obesity Reviews (2024)
sleep-apnea osa glp-1 -
Sanyal AJ, Kaplan LM, Frias JP, et al.
Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial
Nature Medicine . 30 : 2037-2048 (2024)
masld mash liver-fat phase-2 mri-pdff -
Wilding JPH, Batterham RL, Davies M, et al.
Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension
Diabetes, Obesity and Metabolism (2024)
semaglutide weight-regain step-trial
2023
-
Jastreboff AM, Kaplan LM, Frias JP, et al.
Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
New England Journal of Medicine . 389 : 514-526 (2023)
phase-2 obesity weight-loss clinical-trial -
Rosenstock J, Frias JP, Jastreboff AM, et al.
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-comparator controlled, parallel-group, phase 2 trial conducted in the USA
The Lancet . 402 : 529-544 (2023)
phase-2 type-2-diabetes glycemic-control clinical-trial -
Rosenstock J, Frias JP, Rodbard HW, et al.
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-comparator controlled, parallel-group, phase 2 trial conducted in the USA
The Lancet . 402 : 529-544 (2023)
phase-2 type-2-diabetes hba1c clinical-trial -
Thomas MK, Nikooienejad A, Bray R, et al.
Dual GIP and GLP-1 receptor agonist tirzepatide improves beta-cell function and insulin sensitivity in type 2 diabetes
Diabetes Care (2023)
tirzepatide mechanism beta-cell
2022
-
Briere DA, Bueno AB, Gunn EJ, et al.
Mechanisms to elevate endogenous GLP-1 beyond injectable GLP-1 analogs and metabolic surgery
Molecular Metabolism (2022)
glp-1 mechanism review -
Coskun T, Urva S, Roell WC, et al.
LY3437943, a novel triple GIP/GLP-1/glucagon receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept
Cell Metabolism . 34 : 1234-1247.e9 (2022)
preclinical pharmacology mechanism phase-1 -
Coskun T, Urva S, Roell WC, et al.
LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept
Cell Metabolism . 34 : 1234-1247.e9 (2022)
preclinical pharmacology mechanism discovery -
Urva S, Coskun T, Loh MT, et al.
LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial
The Lancet . 400 : 1869-1881 (2022)
phase-1 type-2-diabetes dose-finding pharmacokinetics